Marker Therapeutics Inc
NASDAQ:MRKR

Watchlist Manager
Marker Therapeutics Inc Logo
Marker Therapeutics Inc
NASDAQ:MRKR
Watchlist
Price: 3.8 USD 1.88% Market Closed
Market Cap: 33.9m USD
Have any thoughts about
Marker Therapeutics Inc?
Write Note

Marker Therapeutics Inc
Other

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Marker Therapeutics Inc
Other Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other CAGR 3Y CAGR 5Y CAGR 10Y
Marker Therapeutics Inc
NASDAQ:MRKR
Other
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Other
-$100m
CAGR 3-Years
45%
CAGR 5-Years
22%
CAGR 10-Years
3%
Gilead Sciences Inc
NASDAQ:GILD
Other
-$5.7B
CAGR 3-Years
-238%
CAGR 5-Years
-114%
CAGR 10-Years
-4%
Amgen Inc
NASDAQ:AMGN
Other
-$127m
CAGR 3-Years
-6%
CAGR 5-Years
-20%
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Other
-$398.9m
CAGR 3-Years
-39%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Other
-$1.3B
CAGR 3-Years
-38%
CAGR 5-Years
-53%
CAGR 10-Years
N/A
No Stocks Found

Marker Therapeutics Inc
Glance View

Market Cap
33.8m USD
Industry
Biotechnology

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company is headquartered in Houston, Texas and currently employs 56 full-time employees. The company went IPO on 2016-11-08. The firm specializes in the development and commercialization of T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The firm has developed its lead product candidates from its MultiTAA-specific T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (TAAs), which are tumor targets, and then kill tumor cells expressing those targets. The company has three MultiTAA-specific T cell therapies through clinical development, which include Autologous MultiTAA-specific T cell therapies, Allogeneic MultiTAA-specific T cell therapies and Off-the-shelf MultiTAA-specific T cell therapies. The firm is focused on developing MT-601 for the treatment of advanced unresectable pancreatic cancer.

MRKR Intrinsic Value
3.84 USD
Undervaluation 1%
Intrinsic Value
Price

See Also

Back to Top